Elutia Inc develops proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications... Show more
Get AI intraday signals
A.I. Advisor
published Earnings
ELUT is expected to report earnings to fall 11.76% to -15 cents per share on August 12
Q2'26
Est.
$-0.15
Q1'26
Missed
by $0.02
Q4'25
Beat
by $1.60
Q3'25
Missed
by $0.04
Q2'25
Missed
by $0.07
The last earnings report on May 14 showed earnings per share of -17 cents, missing the estimate of -15 cents. With 13.23K shares outstanding, the current market capitalization sits at 42.57M.